Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products
View Patent ↗Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.
1. A method for collecting a blood component product comprising
selecting for use an adsorption medium consisting essentially of polymeric particles each comprising a hydrophobic core consisting essentially of hydrophobic cross-linked porous divinylbenzene material and a biocompatible hydrophilic coating consisting essentially of biocompatible polyvinylpyrrolidone material, the adsorption medium selected to have a Biocompatibility Index of not greater than 14 derived lay a protocol consisting essentially of
(i) selecting blood indicators which quantify, physiologic changes based upon contact between the adsorption medium and blood, the blood indicators consisting essentially of (1) white blood cell count diminution as a result of contact with the adsorption medium ascertained by Coulter Counter; (2) red blood cell count diminution as a result of contact with the adsorption medium ascertained by Coulter Counter; (3) platelet count diminution as a result of contact with the adsorption medium ascertained by Coulter Counter; (4) leukocytes activation as a result of contact with the adsorption medium ascertained by measuring polymorphonuclear leukocyte elastase concentration (PMN Elastase Concentration); (5) complement activation as a result of contact with the adsorption medium ascertained by measuring anaphylatoxin C3a-desArg concentrations; (6) occurrence of hemolysis as a result of contact with the adsorption medium ascertained by determining concentrations of Lactate dehydrogenase (LDH); and reduction of clot formation as a result of contact with the adsorption medium ascertained by measuring concentrations of thrombin-antithrombin-complex (TAT),
(ii) for each indicator, ascertaining a maximum difference between the indicator values over 25 ml of flow of heparinized blood heparinized to a final concentration of 1.0 IU heparin/ml blood passed through a biocompatible housing without the adsorption medium, comprising a baseline value, and heparinized blood passed through the housing containing the adsorption medium, and for each indicator, expressing the maximum change as a percentage change, relative to the baseline value,
(iii) scoring the percentage change for each indicator as a dimensionless numeric quantity 1, 2, or 3, depending upon the magnitude of the percentage change, in accordance with Table 1,
(iv) after scoring each indicator with a numeric quantity of 1, 2, or 3, adding the numeric quantities scored for all the indicators to obtain a total, the total comprising the Biocompatibility Index, processing the blood drawn from an individual into a blood component product, the processing triggering an incidental generation of cytokines in the blood component product,
collecting the blood component product in a storage container, and
removing the cytokines that are generated during the processing from the blood component product before, during, or after its collection in the storage container by passing the blood component product through the adsorption medium.
2. A method according to claim 1
wherein the blood component product includes a red blood cell component.
3. A method according to claim 1
wherein the blood component product includes a platelet component.
4. A method according to claim 1
wherein the blood component product includes a white blood cell component.
5. A method according to claim 1
wherein the blood component product includes a plasma component.
6. A method according to claim 1
wherein the Biocompatibility Index is not greater than 7.